Ji E. Han

Suwon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation.

Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation.

Journal: Molecular oncology
Published: February 10, 2026

Plasma interleukin-8 as a predictive biomarker for tyrosine kinase inhibitor response in advanced hepatocellular carcinoma.

Plasma interleukin-8 as a predictive biomarker for tyrosine kinase inhibitor response in advanced hepatocellular carcinoma.

Journal: Discover oncology
Published: January 09, 2026

Enhanced pathogen detection and gut microbiome alterations in pyogenic liver abscess: insights from next-generation sequencing.

Enhanced pathogen detection and gut microbiome alterations in pyogenic liver abscess: insights from next-generation sequencing.

Journal: Gut pathogens
Published: October 12, 2025

Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea.

Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea.

Journal: Journal of liver cancer
Published: July 22, 2025

Serum Extracellular Vesicle-Associated GULP1 Is a Key Indicator of Hepatocellular Carcinoma.

Serum Extracellular Vesicle-Associated GULP1 Is a Key Indicator of Hepatocellular Carcinoma.

Journal: Oncology research
Published: July 15, 2025

CTC-537E7.3 as a Liver-Specific Biomarker for Hepatocellular Carcinoma: Diagnostic and Prognostic Implications.

CTC-537E7.3 as a Liver-Specific Biomarker for Hepatocellular Carcinoma: Diagnostic and Prognostic Implications.

Journal: Current issues in molecular biology
Published: June 13, 2025

Reply to correspondence 2 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".

Reply to correspondence 2 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".

Journal: Clinical and molecular hepatology
Published: May 26, 2025

Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria.

Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria.

Journal: Journal of liver cancer
Published: May 25, 2025

A Novel Liver-Specific Pseudogene Biomarker, BMS1P8, for Diagnosis and Prognosis in Hepatocellular Carcinoma.

A Novel Liver-Specific Pseudogene Biomarker, BMS1P8, for Diagnosis and Prognosis in Hepatocellular Carcinoma.

Journal: Frontiers in bioscience (Landmark edition)
Published: May 19, 2025

Uncovering the MET-TRIB3-FOXO1 axis: A novel target in MET-driven hepatocellular carcinoma: Editorial on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".

Uncovering the MET-TRIB3-FOXO1 axis: A novel target in MET-driven hepatocellular carcinoma: Editorial on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".

Journal: Clinical and molecular hepatology
Published: May 09, 2025

Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host-microbe signaling and highlights 2-hydroxyisocaproate as a potential effector.

Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host-microbe signaling and highlights 2-hydroxyisocaproate as a potential effector.

Journal: Clinical and molecular hepatology
Published: May 04, 2025

GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma.

GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma.

Journal: Clinical and molecular hepatology
Published: November 19, 2024
Showing 1-12 of 39

Last Updated: 09/26/2026